小柯机器人

近日，美国加州大学旧金山分校Adam L. Boxer等研究人员发现，血浆磷酸化tau181蛋白在阿尔茨海默氏病（AD）和额颞叶变性预测中具有诊断价值。相关论文于2020年3月2日在线发表于《自然—医学》杂志。

研究人员检查了在残基181处磷酸化的血浆tau蛋白（pTau181）是否可以区分临床诊断或尸检确认的AD与额颞叶变性。与对照组相比，AD中血浆中pTau181的浓度增加了3.5倍，并且与临床诊断（接受者工作特征区域在0.894曲线下）和尸体确认的额颞叶变性（在0.878曲线下）有所区别。血浆pTau181可以识别β-淀粉样蛋白正电子发射断层扫描（PET）阳性的个体，而与临床诊断无关，并且与18F-flortaucipir PET测量的tau蛋白沉积相关。血浆pTau181对筛查与AD相关的tau病理可能有用。

据了解，随着新型AD疗法的发展，简单、广泛可用的筛查测试需要用于确定哪些患有认知或行为下降症状的个体应进一步评估以开始治疗。与目前批准的脑脊液或β淀粉样蛋白PET诊断测试相比，基于血液的AD测试是一种侵入性较小，价格较低的筛查工具。

附：英文原文

Title: Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

Author: Elisabeth H. Thijssen, Renaud La Joie, Amy Wolf, Amelia Strom, Ping Wang, Leonardo Iaccarino, Viktoriya Bourakova, Yann Cobigo, Hilary Heuer, Salvatore Spina, Lawren VandeVrede, Xiyun Chai, Nicholas K. Proctor, David C. Airey, Sergey Shcherbinin, Cynthia Duggan Evans, John R. Sims, Henrik Zetterberg, Kaj Blennow, Anna M. Karydas, Charlotte E. Teunissen, Joel H. Kramer, Lea T. Grinberg, William W. Seeley, Howie Rosen, Bradley F. Boeve, Bruce L. Miller, Gil D. Rabinovici, Jeffrey L. Dage, Julio C. Rojas, Adam L. Boxer

Issue&Volume: 2020-03-02

Abstract: With the potential development of new disease-modifying Alzheimer’s disease (AD) therapies, simple, widely available screening tests are needed to identify which individuals, who are experiencing symptoms of cognitive or behavioral decline, should be further evaluated for initiation of treatment. A blood-based test for AD would be a less invasive and less expensive screening tool than the currently approved cerebrospinal fluid or amyloid β positron emission tomography (PET) diagnostic tests. We examined whether plasma tau phosphorylated at residue 181 (pTau181) could differentiate between clinically diagnosed or autopsy-confirmed AD and frontotemporal lobar degeneration. Plasma pTau181 concentrations were increased by 3.5-fold in AD compared to controls and differentiated AD from both clinically diagnosed (receiver operating characteristic area under the curve of 0.894) and autopsy-confirmed frontotemporal lobar degeneration (area under the curve of 0.878). Plasma pTau181 identified individuals who were amyloid β-PET-positive regardless of clinical diagnosis and correlated with cortical tau protein deposition measured by 18F-flortaucipir PET. Plasma pTau181 may be useful to screen for tau pathology associated with AD.

DOI: 10.1038/s41591-020-0762-2

Source: https://www.nature.com/articles/s41591-020-0762-2

Nature Medicine：《自然—医学》，创刊于1995年。隶属于施普林格·自然出版集团，最新IF：87.241
官方网址：https://www.nature.com/nm/
投稿链接：https://mts-nmed.nature.com/cgi-bin/main.plex